KRAS and RASopathy: Since mutant allele-specific covalent inhibitor of oncogenic variants of KRAS-G12C (not KRAS G12D or KRAS G12V), ARS1620, and MRTX849 are in the clinical development (recently presented at the NCI/NIH-sponsored session titled New NCI Collaborative Initiatives on Rare Tumors and RASopathies, presentation by Prof. McCormick, AACR Annual Meeting, Atlanta 2019), a similar allele-specific covalent inhibitor(s) of oncogenic variants of RAC1-P29S may have a significant clinical application.